| 000 | 01743 a2200481 4500 | ||
|---|---|---|---|
| 005 | 20250516014302.0 | ||
| 264 | 0 | _c20110621 | |
| 008 | 201106s 0 0 eng d | ||
| 022 | _a1029-2403 | ||
| 024 | 7 |
_a10.3109/10428194.2010.536601 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMoise, Laura | |
| 245 | 0 | 0 |
_aMethotrexate- and/or cytarabine-based chemotherapy may be effective and safe in solid-organ transplant recipients with primary central nervous system lymphomas. _h[electronic resource] |
| 260 |
_bLeukemia & lymphoma _cMar 2011 |
||
| 300 |
_a521-4 p. _bdigital |
||
| 500 | _aPublication Type: Controlled Clinical Trial; Letter | ||
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xadverse effects |
| 650 | 0 | 4 |
_aCentral Nervous System Neoplasms _xdrug therapy |
| 650 | 0 | 4 |
_aCytarabine _xadministration & dosage |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aFeasibility Studies |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunosuppression Therapy _xadverse effects |
| 650 | 0 | 4 |
_aLymphoma _xdrug therapy |
| 650 | 0 | 4 |
_aMethotrexate _xadministration & dosage |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 |
_aOrgan Transplantation _xmethods |
| 650 | 0 | 4 | _aRecurrence |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aTransplantation |
| 650 | 0 | 4 | _aTreatment Outcome |
| 700 | 1 | _aMatta, Clemence | |
| 700 | 1 | _aHanna, Colette | |
| 700 | 1 | _aPilorge, Sylvain | |
| 700 | 1 | _aFermé, Christophe | |
| 700 | 1 | _aDurrbach, Antoine | |
| 700 | 1 | _aRibrag, Vincent | |
| 773 | 0 |
_tLeukemia & lymphoma _gvol. 52 _gno. 3 _gp. 521-4 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.3109/10428194.2010.536601 _zAvailable from publisher's website |
| 999 |
_c20424833 _d20424833 |
||